EP1601356A1 - Crystalline non-solvated 1-(4-(2-piperidinylethoxy)phenoxy)-2-(4-methanesulfonylphenyl)-6-hydroxynaphthalene hydrochloride - Google Patents

Crystalline non-solvated 1-(4-(2-piperidinylethoxy)phenoxy)-2-(4-methanesulfonylphenyl)-6-hydroxynaphthalene hydrochloride

Info

Publication number
EP1601356A1
EP1601356A1 EP04703963A EP04703963A EP1601356A1 EP 1601356 A1 EP1601356 A1 EP 1601356A1 EP 04703963 A EP04703963 A EP 04703963A EP 04703963 A EP04703963 A EP 04703963A EP 1601356 A1 EP1601356 A1 EP 1601356A1
Authority
EP
European Patent Office
Prior art keywords
volumes
methanesulfonylphenyl
compound
iii
phenoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04703963A
Other languages
German (de)
English (en)
French (fr)
Inventor
David Michael Remick
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/IB2003/003349 external-priority patent/WO2004009086A1/en
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of EP1601356A1 publication Critical patent/EP1601356A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP04703963A 2003-02-25 2004-01-21 Crystalline non-solvated 1-(4-(2-piperidinylethoxy)phenoxy)-2-(4-methanesulfonylphenyl)-6-hydroxynaphthalene hydrochloride Withdrawn EP1601356A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US45023303P 2003-02-25 2003-02-25
US450233P 2003-02-25
PCT/IB2003/003349 WO2004009086A1 (en) 2002-07-22 2003-07-16 Selective estrogen receptor modulators containing a phenylsulfonyl group
WOPCT/IB03/03349 2003-07-16
PCT/US2004/000020 WO2004075894A1 (en) 2003-02-25 2004-01-21 Crystalline non-solvated 1-(4-(2-piperidinylethoxy)phenoxy)-2-(4-methanesulfonylphenyl)-6-hydroxynaphthalene hydrochloride

Publications (1)

Publication Number Publication Date
EP1601356A1 true EP1601356A1 (en) 2005-12-07

Family

ID=32929435

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04703963A Withdrawn EP1601356A1 (en) 2003-02-25 2004-01-21 Crystalline non-solvated 1-(4-(2-piperidinylethoxy)phenoxy)-2-(4-methanesulfonylphenyl)-6-hydroxynaphthalene hydrochloride

Country Status (8)

Country Link
EP (1) EP1601356A1 (hr)
AU (1) AU2004216258B2 (hr)
BR (1) BRPI0407690A (hr)
CA (1) CA2512663A1 (hr)
HR (1) HRP20050675A2 (hr)
MX (1) MXPA05009098A (hr)
NO (1) NO20054400L (hr)
WO (1) WO2004075894A1 (hr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1713770A1 (en) * 2004-01-29 2006-10-25 Eli Lilly And Company Selective estrogen receptor modulators
AU2006290309B2 (en) 2005-09-12 2012-04-05 Actelion Pharmaceuticals Ltd. Stable pharmaceutical composition comprising a pyrimidine-sulfamide
MX2010001837A (es) 2007-08-17 2010-03-10 Actelion Pharmaceuticals Ltd Derivados de 4-pirimidinasulfamida.

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7501441B1 (en) 1994-09-20 2009-03-10 Eli Lilly And Company Naphthyl compounds, intermediates, processes, compositions, and methods
US5484798A (en) 1994-09-20 1996-01-16 Eli Lilly And Company Benzothiopene compounds, compositions, and method of inhibiting restenosis
US6703407B1 (en) 1994-09-20 2004-03-09 Eli Lilly And Company Benzofuran compounds, compositions, and methods
US5998401A (en) 1995-02-28 1999-12-07 Eli Lilly And Company Naphthyl compounds, intermediates, compositions, and methods
US5510357A (en) 1995-02-28 1996-04-23 Eli Lilly And Company Benzothiophene compounds as anti-estrogenic agents
US6307047B1 (en) 1997-08-22 2001-10-23 Abbott Laboratories Prostaglandin endoperoxide H synthase biosynthesis inhibitors
US5929090A (en) 1997-09-12 1999-07-27 Eli Lilly And Company 2-aryl-3-aminoaryloxynaphthy1 compounds, intermediates, compositions and methods
CA2490580C (en) * 2002-07-22 2012-12-11 Eli Lilly And Company Selective estrogen receptor modulators containing a naphthalene group

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2004075894A1 *

Also Published As

Publication number Publication date
WO2004075894A1 (en) 2004-09-10
MXPA05009098A (es) 2005-11-17
AU2004216258A1 (en) 2004-09-10
NO20054400L (no) 2005-09-22
AU2004216258B2 (en) 2006-10-19
HRP20050675A2 (en) 2005-10-31
CA2512663A1 (en) 2004-09-10
BRPI0407690A (pt) 2006-03-01

Similar Documents

Publication Publication Date Title
CZ291207B6 (cs) Naftylová sloučenina, způsoby její přípravy, farmaceutický prostředek s jejím obsahem, její pouľití a meziprodukty
JPH10231292A (ja) ２−アリール−３−アミノアリールオキシナフチル化合物、中間体、組成物及び方法
AU2004216258B2 (en) Crystalline non-solvated 1-(4-(2-piperidinylethoxy)phenoxy)-2-(4-methanesulfonylphenyl)-6-hydroxynaphthalene hydrochloride
CZ64399A3 (cs) Amorfní derivát benzothiofenu, způsob jeho přípravy a farmaceutický prostředek, který je obsahuje
KR100697177B1 (ko) 신규 결정질 형태의6-히드록시-3-(4-[2-(피페리딘-1-일)에톡시]페녹시)-2-(4-메톡시페닐)벤조[ｂ]티오펜 히드로클로라이드
LV12733B (lv) 6-hidroksi-3-(4-[2-(piperidin-1-il) etoksi] fenoksi)-2-(4-metoksifenil) benzo [b] tiofēna hidrohlorīda jauna kristāliska forma
ZA200506547B (en) Crystalline non-solvated (1-(4-(2-piperidinylethoxy) phenoxy-2-(4-methanesulfonylphenyl)-6-hydroxynaphthalene hydro-chloride
US20060167051A1 (en) Crystalline non-solvated 1-(4-(2-piperidinylethoxy)phenoxy)-2-(4-methanesulfonylphenyl)-6-hydroxynaphthalene hydrochloride
US20080200507A1 (en) Crystalline Non-Solvated Methanesulfonic Acid Salt of 1-(4-(2-Piperidinylethoxy)Phenoxy)-2-(3-Hydroxyphenyl)-6-Hydroxynaphthalene
US20040014672A1 (en) Novel crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene hydrochloride
EP1401446B1 (en) Tetrahydroquinolin derivatives for the inhibition of diseases associated with estrogen deprivation or with an aberrant physiological response to endogenous estrogen
UA80465C2 (en) Crystalline non-solvated 1-(4-2-piperidinylethoxy)phenoxy)-2-(4-methane-sulfonylphenyl)-6-hydroxynaphthalene hydrochloride
SK286346B6 (en) Stabilized formulations of 6-hydroxy-3-(4-[2-(piperidin-1-yl) ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene and salts thereof
US6653479B1 (en) Crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b] thiophene hydrochloride
NZ506046A (en) A novel crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methanoxyphenyl)benzo[b]thiophene hydrochloride

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050926

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1085925

Country of ref document: HK

17Q First examination report despatched

Effective date: 20061114

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20090421

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1085925

Country of ref document: HK